SIGA Technologies and the Development of Tpoxx
The landscape of antiviral defense has been significantly shaped by the work of SIGA Technologies, a company focused on creating broad-spectrum antiviral candidates to combat high-threat pathogens. Central to their portfolio is tecovirimat, marketed as Tpoxx, a small molecule antiviral treatment designed to treat and prevent orthopoxviruses.
Key Facts
- Tpoxx (tecovirimat) is approved for the treatment of smallpox and other poxviruses.
- The drug is available in both oral and intravenous (IV) formulations.
- SIGA Technologies secured a major contract exceeding $400 million with BARDA for the drug's development and distribution.
- Tpoxx is approved for use in the United States, Canada, and the European Union.
- The drug is used for smallpox, monkeypox, cowpox, and vaccinia complications.
The Path to Development and Funding
The journey of SIGA Technologies began with critical support from the National Institutes of Health (NIH). In September 2009, the company received a $1.6 million research fund for its broad-spectrum antiviral candidates. This was followed in August 2011 by a $7.7 million grant from the NIH specifically to develop treatments for Lassa fever and other arenaviruses.
A pivotal moment occurred in 2011 when SIGA entered into a contract worth over $400 million with the United States Biomedical Advanced Research and Development Authority (BARDA), the agency responsible for preparing the U.S. for public health emergencies. This partnership focused on the development and distribution of Tpoxx.
[ไม่มีภาพประกอบ]Legal Challenges and Financial Hurdles
Despite its scientific progress, the company faced significant legal and financial instability. In 2011, SIGA was ordered to pay $232 million in damages following a legal dispute with PharmAthene regarding the rights to tecovirimat. These pressures culminated in 2014, when the company filed for Chapter 11 bankruptcy protection to avoid paying a court bond after losing a contract lawsuit.
Regulatory Approval and Global Expansion
The regulatory trajectory for Tpoxx accelerated in 2018. In May, an FDA advisory committee determined that the benefits of the small molecule antiviral outweighed its potential risks. Following an evaluation involving 359 healthy human volunteers, the FDA granted approval for Tpoxx in July 2018.
The company continued to expand the drug's utility and accessibility:
- 2019: Signed a $23 million contract with the U.S. Department of Defense for post-exposure prophylaxis (preventative treatment after exposure).
- 2021: Submitted an intravenous (IV) version of Tpoxx to the FDA, which received approval in May 2022.
- December 2021: Health Canada approved oral Tpoxx for adults and pediatric patients weighing at least 13kg.
- January 2022: The European Medicines Agency approved oral tecovirimat for smallpox, monkeypox, cowpox, and vaccinia complications in patients weighing at least 13kg.
Notably, the intravenous version of Tpoxx has no lower weight limit and can be administered to infants under the Investigational New Drug protocol. To address emerging health threats, the FDA and the Centers for Disease Control and Prevention (CDC) have relaxed regulations to simplify the prescription of Tpoxx for monkeypox patients in the United States.
[ไม่มีภาพประกอบ]Tpoxx Approval and Usage Summary
| Region/Agency | Approval Date | Formulation | Indications/Patient Criteria |
|---|---|---|---|
| USA (FDA) | July 2018 / May 2022 | Oral & IV | Smallpox, Monkeypox (IV for infants) |
| Canada (Health Canada) | December 2021 | Oral | Adults and pediatric patients ≥ 13kg |
| European Union (EMA) | January 2022 | Oral | Smallpox, Monkeypox, Cowpox, Vaccinia ≥ 13kg |
Frequently Asked Questions
What is Tpoxx?
Tpoxx, also known as tecovirimat, is a small molecule antiviral drug developed by SIGA Technologies to treat and prevent smallpox and other orthopoxviruses.
Which diseases is tecovirimat approved to treat?
Depending on the region, it is approved for smallpox, monkeypox, cowpox, and complications arising from vaccinia.
Is Tpoxx available for children?
Yes. The oral version is approved for pediatric patients weighing at least 13kg in Canada and the EU. The intravenous (IV) version has no lower weight cap and can be used in infants under the Investigational New Drug protocol.
How did the U.S. government support the distribution of Tpoxx?
The U.S. government, through BARDA, contracted SIGA Technologies for the drug's development and distribution, which included the delivery of approximately 590,000 courses to the Strategic National Stockpile (SNS) in 2013.
What is the difference between the oral and IV versions of Tpoxx?
The oral version is used for patients meeting specific weight requirements (typically 13kg or more), while the intravenous version allows for treatment in patients regardless of weight, including infants.